ReviewInternational journal of molecular sciences2022
Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis.Frontiers in immunology · 2025Pooled it
- Clustering of rheumatoid arthritis patients: an unsupervised machine learning approach for characterizing the TNFi response.Immunologic research · 2026Article
- Prognostic value of longitudinal antinuclear antibody dynamics in rheumatoid arthritis: a retrospective cohort study.Frontiers in immunology · 2026Article
- TPMT and HLA-DQ Allelic Variants in Relation to Drug Response, Safety and Need for Therapy Optimization in Pediatric Inflammatory Bowel Disease.Children (Basel, Switzerland) · 2025Article
- The Inflammatory Link of Rheumatoid Arthritis and Thrombosis: Pathogenic Molecular Circuits and Treatment Approaches.Current issues in molecular biology · 2025Review
- Exploring the Potential Value of Lactylation and Macrophage Polarization-Related Genes as Biomarkers for TNF-α Inhibitor Response in Inflammatory Bowel Disease.Journal of inflammation research · 2025Article
- Emodin mitigates rheumatoid arthritis through direct binding to TNF-α.Frontiers in pharmacology · 2025Article
- The 12-Membered TNFR1 Peptide, as Well as the 16-Membered and 6-Membered TNF Peptides, Regulate TNFR1-Dependent Cytotoxic Activity of TNF.International journal of molecular sciences · 2024Article
- An in vitro study elucidating the synergistic effects of aqueous cinnamon extract and an anti-TNF-α biotherapeutic: implications for a complementary and alternative therapy for non-responders.BMC complementary medicine and therapies · 2024Article
- Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis.Arthritis research & therapy · 2023Article
- Mononuclear cells from patients with rhupus are influenced by TNF in their production of gp130/sIL-6Rb and APRIL.Lupus science & medicine · 2023Article
- A compendium of mitochondrial molecular characteristics provides novel perspectives on the treatment of rheumatoid arthritis patients.Journal of translational medicine · 2023Article
- The Effectiveness of Laser Applications and Photodynamic Therapy on Relevant Periodontal Pathogens (Bioengineering (Basel, Switzerland) · 2023Article
- Clinical Value ofJournal of personalized medicine · 2022Article
- Role ofPharmaceutics · 2022Article
- The intracellular cation channel TMEM176B as a dual immunoregulator.Frontiers in cell and developmental biology · 2022Review
- Detecting potential mechanism of vitamin D in treating rheumatoid arthritis based on network pharmacology and molecular docking.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Rheumatoid arthritis (RA) is the most commonly occurring chronic inflammatory arthritis, the exact mechanism of which is not fully understood. Tumor Necrosis Factor (TNF)-targeting drugs has been shown to exert high effectiveness for RA, which indicates the key importance of this cytokine in this disease. Nevertheless, the response to TNF inhibitors varies, and approximately one third of RA patients are non-responders, which is explained by the influence of genetic factors. Knowledge in the field of pharmacogenomics of anti-TNF drugs is growing, but has not been applied in the clinical practice so far. Different genome-wide association studies identified a few single nucleotide polymorphisms associated with anti-TNF treatment response, which largely map genes involved in T cell function. Studies of the gene expression profile of RA patients have also indicated specific gene signatures that may be useful to develop novel prognostic tools. In this article, we discuss the significance of TNF in RA and present the current knowledge in pharmacogenomics related to anti-TNF treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.